Beyond myeloid malignancies, selective TET inhibition may have a role in TET2-associated CH by restricting the expansion of TET2-deficient clones, potentially reducing the risk of malignant transformation as well as cardiac co-morbidities (Guan et al., 2021). This evidence concerns the gene TET2 and cyclic hematopoiesis.